NCT05710874

Brief Summary

The goal of this randomized clinical trial is to compare the influence of casein phosphopeptide amorphous calcium phosphate (CPP-ACP), CPP-ACP in combination with fluoride (CPP-ACPF), high fluoride concentration, and conventional fluoride toothpaste on the color and size of white spot lesions (WSLs) in orthodontic patients following bracket removal.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 23, 2016

Completed
6.3 years until next milestone

First Submitted

Initial submission to the registry

January 11, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 2, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 29, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 29, 2023

Completed
Last Updated

August 24, 2023

Status Verified

August 1, 2023

Enrollment Period

6.5 years

First QC Date

January 11, 2023

Last Update Submit

August 23, 2023

Conditions

Keywords

orthodonticsorthodontic bracketsdental cariesdecalcificationcaseinsfluorides

Outcome Measures

Primary Outcomes (4)

  • Evolution of the relative area of the white spot lesions

    ImageJ® (National Institutes of Health, Bethesda, MD, USA) was used to measure the relative area. In order to measure the relative area of the white spot lesions, the affected tooth was trimmed out of the original photo and the entire buccal surface was measured in absolute pixels. After this, the white spot lesion was outlined and measured in pixels.

    The change in relative area between the end of orthodontic treatment (T0) and 2 months after the end of orthodontic treatment (T1) is measured.

  • Evolution of the relative area of the white spot lesions

    ImageJ® (National Institutes of Health, Bethesda, MD, USA) was used to measure the relative area. In order to measure the relative area of the white spot lesions, the affected tooth was trimmed out of the original photo and the entire buccal surface was measured in absolute pixels. After this, the white spot lesion was outlined and measured in pixels.

    The change in relative area between the end of orthodontic treatment (T0) and 4 months after the end of orthodontic treatment (T2) is measured. Patients participate in the study for 4 months.

  • Evolution of the Andersson Index of the white spot lesions

    The Andersson Index (AI) was determined on the basis of the clinical pictures.

    The change in Andersson Index between the end of orthodontic treatment (T0) and 2 months after the end of orthodontic treatment (T1) is measured.

  • Evolution of the Andersson Index of the white spot lesions

    The Andersson Index (AI) was determined on the basis of the clinical pictures.

    The change in Andersson Index between the end of orthodontic treatment (T0) and 4 months after the end of orthodontic treatment (T2) is measured. Patients participate in the study for 4 months.

Secondary Outcomes (3)

  • Gingival Index

    The Gingival Indexis measured at the end of orthodontic treatment (T0), at 2 months after the end of orthodontic treatment (T1) and at 4 months after the end of orthodontic treatment (T2). Patients participate in the study for 4 months.

  • Plaque Index

    The Plaque Index is measured at the end of orthodontic treatment (T0), at 2 months after the end of orthodontic treatment (T1) and at 4 months after the end of orthodontic treatment (T2). Patients participate in the study for 4 months.

  • Patient's use of the tooth paste

    The patient's use of the tooth paste is determined at 2 months after the end of orthodontic treatment (T1) and at 4 months after the end of orthodontic treatment (T2). Patients participate in the study for 4 months.

Study Arms (4)

CPP-ACP paste

EXPERIMENTAL

Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.

Other: CPP-ACP paste

CPP-ACPF paste

EXPERIMENTAL

Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoride) paste (MI Paste Plus®) in addition to twice daily use of conventional toothpaste..

Other: CPP-ACPF paste

1.25% fluoride gel

EXPERIMENTAL

Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.

Other: 1.25% fluoride gel

Conventional

PLACEBO COMPARATOR

Twice daily use of conventional toothpaste.

Other: Conventional

Interventions

Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.

CPP-ACP paste

Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.

CPP-ACPF paste

Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.

1.25% fluoride gel

Twice daily use of conventional toothpaste.

Conventional

Eligibility Criteria

Age12 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients treated with fixed orthodontic appliances at the Ghent University Hospital who developed at least three WSLs at debonding were included. Informed consent had to be obtained from the patient, both verbally and written.

You may not qualify if:

  • Patients were excluded from the study if enamel demineralization was already present before orthodontic treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Ghent

Ghent, Oost-Vlaanderen, 9000, Belgium

Location

MeSH Terms

Conditions

Dental Caries

Interventions

Congresses as Topic

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

OrganizationsHealth Care Economics and Organizations

Study Officials

  • Levine Gavel

    Postgraduate Orthodontics

    PRINCIPAL INVESTIGATOR
  • Valentina Elena Arevalo Cabrera

    Master Student Oral Health Sciences

    PRINCIPAL INVESTIGATOR
  • Deseyne Thomas

    Alumnus Orthodontics

    PRINCIPAL INVESTIGATOR
  • Guy AM De Pauw

    Professor dr. in Orthodontics

    STUDY CHAIR
  • Noëmi MC De Roo

    Doctorate in Orthodontics

    STUDY CHAIR
  • Liesbeth Temmerman

    dr. in Orthodontics

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2023

First Posted

February 2, 2023

Study Start

September 23, 2016

Primary Completion

March 29, 2023

Study Completion

March 29, 2023

Last Updated

August 24, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations